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Abstract
Background: Barrett's esophagus (BE) is caused by gastroesophageal reflux with consecutive mucosal inflammation, 
predisposing patients to the development of esophageal adenocarcinoma (EAC). We investigated changes in T cell-
related mucosal combinatorial molecular protein patterns in both diseases using the novel Multi-Epitope-Ligand-
Cartography, a unique robotic whole-cell imaging technology that simultaneously visualizes dozens of proteins in 
structurally intact tissues and correlates cellular localization of proteins with function.
Results: Biopsies were taken during endoscopy from BE, EAC, and normal control tissue, and proteomic microscopy 
was performed on 32 different epitopes. When the significance level was set to p < 0.0005 and the search depth to five 
antibody combinations, controls and BE can be differentiated by 63, controls and EAC by 3222, and BE from EAC by 
1521 distinct protein combinations.
For example, the number of activated apoptotic naïve and memory T cells was significantly increased only in BE, whereas
the number of activated apoptotic helper and regulatory T cells was significantly elevated in BE and EAC. In contrast, the
number of activated apoptotic cytotoxic T cells was significantly elevated only in EAC. Confirming different pathways in BE
and EAC, the number of T lymphocytes with p53 expression and downregulation of bcl2 expression (CD3+p53+Bcl2-NfkB-)
was significantly increased in EAC compared to BE and controls. Interestingly, the number of precursor T cells (CD7+) was
significantly elevated only in EAC. These cells lack Bax and caspase-8, suggesting impaired apoptosis in the early stages of
T cell differentiation.
Conclusion: Proteomic analysis showed for the first time that proteins, which are critically involved in the mucosal 
immune system of the esophagus, are distinctly expressed in BE and EAC, whereas others are comparably altered in 
both diseases, suggesting that many pathogenic events might be shared by both diseases. Topological proteomic 
analysis, therefore, helps us to understand the different pathogenic events in the underlying disease pathways.
Background
In the recently updated guidelines Barrett's esophagus is
defined as endoscopically apparent displacement of the
squamocolumnar junction proximal to the gastroesopha-
geal junction with histopathological confirmation of
intestinal metaplasia characterized by goblet cells [1,2]. It
is widely accepted that metaplasia develops as a conse-
quence of gastro-esophageal reflux disease and may cause
esophageal adenocarcinoma via progression of low- and
high-grade intraepithelial neoplasia [3-5]. But in contrast
to the relatively high incidence of reflux symptoms of 10-
20% in the Western population [6], the prevalence of Bar-
rett's metaplasia in patients undergoing an upper endos-
copy for gastroesophageal reflux disease is only about
10% [7,8]. Despite the comparatively low annual inci-
dence rate for developing an esophageal adenocarcinoma
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of approximately 0.5% for patients with BE [9], research-
ers focus on the mechanisms involved in the metaplasia-
dysplasia-carcinoma sequence because of the poor prog-
nosis of this adenocarcinoma. However, despite the fact
that inflammation is a critical component of tumor pro-
gression [10], current knowledge of the molecular mech-
anisms of EAC carcinogenesis on a cellular level is largely
limited to the role of epithelial cells. Since T cells trigger
inflammation, their distribution and function needs to be
investigated to provide a better understanding of EAC
carcinogenesis. The cellular environment and spatial
arrangements of T cells determines their function. There-
fore analyzing the phenotype of cellular components in
morphologically intact fixed tissue is a promising
approach for uncovering distinct protein expression pat-
terns that are potentially critically involved in cancer
development.
The novel Multi-Epitope-Ligand Cartography technol-
ogy has been used by our group and others to perform
systematic high-content proteomic analysis of colorectal
cancer [11], psoriasis [12], murine hippocampus [13],
Crohn's disease, and ulcerative colitis [14]. With the cre-
ation of a highly flexible multiplex detection system the
use of fluorescent in situ protein detection has been
improved. This unique robotic whole-cell imaging tech-
nology is able to simultaneously visualize dozens of pro-
teins in structurally intact cells or tissue. The highly
complex information generated by MELC is processed
through advanced data analysis and visualization soft-
ware to identify protein networks that play a crucial role
in biological processes. The advantage of using a multidi-
mensional microscopic robot technology for high-
throughput protein recognition allows us to detect the
considerable amount of 4.3 × 109  protein expression
arrays and enables the generation of a protein collocation
map, which can be summarized as a toponome.
Our study represents the first systematic, in situ inves-
tigation of T cell-related protein expression patterns and
their modification in the tissue of BE and EAC patients.
By comparing the protein expression pattern of healthy
controls with that of BE and EAC, we ultimately aimed to
reveal changes in the expression and distribution of key
proteins which in the multistep sequence from normal
squamous epithelium via Barrett's metaplasia may finally
lead to esophageal adenocarcinoma.
Results
Exploring combinatorial molecular phenotypes within the 
esophageal mucosa in BE, EAC and controls
We previously confirmed the reproducibility and robust-
ness of the MELC technology to adequately investigate
protein expression patterns of the intestinal mucosa [14].
Given the advantages of this technology for exploring not
only single markers, but also complex protein expression
patterns, our first question of general interest focused on
the absolute number of significant different combinato-
rial molecular phenotypes (CMP). When the significance
level was set to p < 0.0005 (t-test) and the search depth to
mostly five antibody combinations, controls and BE can
be differentiated by 63, but controls and EAC by 3222,
and BE from EAC by 1521 distinct protein combinations.
Further analysis of the margin of the respective differ-
ences revealed that, within the control vs. EAC compari-
son, most CMPs displayed threefold and tenfold
differences whereas a comparison of normal vs. BE shows
o n l y  1 0  C M P s  t h a t  w e r e  t e n f o l d  i n c r e a s ed  i n  B a r r e t t ' s
esophagus (Table 1).
Mucosal T-cell distribution in the esophagus
Aiming to define the T-cell populations within the distal
esophagus, we evaluated the relative frequency of T-cell
phenotypes in the three entities. Interestingly, T-helper
cells (CD4+) were the most present T cells in the mucosa
of control and BE, whereas precursor T lymphocytes
(CD7+) are the most frequent T cell population in EAC
(Figure 1a). Also, the ranking of natural killer cells
(CD56+) decreases from 6th position in controls to 8th
position in BE to the last position in EAC. It was noted
that, next to T cells, neutrophiles (CD15+) were compara-
bly expressed in all three entities.
Apoptotic activity and NfkB expression within the 
esophageal mucosa
Given the fact that dysregulation of apoptosis and cell
activation are central hallmarks of carcinogenesis [15,16],
Table 1: Numeric distribution of differentially expressed CMP motifs in control, BE and EAC
3-fold up 10-fold up 3-fold down 10-fold down
Control vs. BE 47 10 0 0
Control vs. EAC 2483 1056 232 99
BE vs. EAC 807 219 201 43
The given values are the total numbers of significantly up- and down-regulated expression of combinatorial molecular phenotype motifs 
within the two groups (p < 0.0005).Berndt et al. Molecular Cancer 2010, 9:177
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we went on to analyze the relative distribution of apop-
totic cell markers as well as NfkB protein expression as a
marker of cell activation within the esophageal mucosa of
the three groups. As shown in Figure 1b not only NfkB,
but also the distribution of centrally important apoptotic
markers as well as p53 significantly varied between con-
trols, BE, and EAC.
31 most frequent CMPs are distinct in control, BE and EAC
The results so far uncovered significant differences in
protein expression profiles in controls, BE, and EAC and
thus, using the MELC technology, we visualized the 31
most frequently expressed CMPs (Figures 2a-c). Obvious
differences between the images confirmed the distinct
protein expression patterns between the three groups,
prompting us to uncover the respective combinatorial
molecular phenotypes in detail.
Distinct T cell CMP expression in control, Barrett and EAC 
mucosa
The important role of inflammation in the development
of cancer is widely accepted [10], and the function of T
lymphocytes play a central role within this process. Our
analysis revealed that although the relative frequency of
the single marker CD3+ is comparable in all groups (data
not shown), the co- and anti-localization of further mark-
ers uncovered significant differences of T-cell death path-
ways between controls, BE, and EAC.
As depicted in Figure 3a, the number of activated (NfkB+)
T cells (CD3+) with expression of caspase 3 and caspase 8 is
increased in BE and EAC compared to the controls. Further
investigations showed that apoptotic naïve T cells
(CD45RA+CD8-caspase3+caspase8+NfkB+) and apoptotic
memory T cells (CD45R0+CD8-caspase3+caspase8+NfkB+)
are increased in BE compared to the controls and EAC
Figure 1 Schematic demonstration of the T-cell distribution and expression of apoptotic markers including NfkB within the esophageal 
mucosa in control, BE and EAC. A T-helper cells are the most frequent T cells in control and BE, whereas in EAC T precursor cells are the most frequent 
T cells. The position of natural killer cells (CD56+) decreases from controls via BE to the last position of EAC. B The relative frequency of central apoptotic 
markers as well as p53 and NfkB varies between control, BE and EAC. Biopsies were taken from control, BE, and EAC mucosa and MELC staining cycles, 
and data processing was performed as described in the Experimental Procedures section.Berndt et al. Molecular Cancer 2010, 9:177
http://www.molecular-cancer.com/content/9/1/177
Page 4 of 10
(Figure 3b and 3c). In contrast, apoptotic T-helper cells
(CD4+CD8-caspase3+caspase8+NfkB+) and regulatory T
cells (CD4+CD25+CD8-caspase3+caspase8+NfkB+) are
increased in both BE and EAC (Figure 3d and 3e).
However, the number of apoptotic cytotoxic T cells
(CD8+CD4-caspase3+caspase8+NfkB+) is significantly
elevated only in EAC (Figure 3f).
Although p53 is a key player in carcinogenesis [17], its
expression in T-helper cells (CD4+), cytotoxic T cells
(CD8+), naïve T cells (CD45RA+) as well as memory T
cells (CD45R0+) was comparable in all groups (data not
shown). However, the number of CD3+p53+Bcl2-NfkB-
cells was increased in EAC compared to BE and the con-
trols (Figure 4).
As expected, the highest number of CMP motifs out of
the 4.3 × 109 possible CMP motifs exists between the con-
trol group and EAC. Exploring which proteins are dis-
tinctly regulated in the progression from BE to EAC, we
examined the motifs containing precursor T lymphocytes
(CD7+) and natural killer cells (CD56+) based on the
change in their relative frequency within the three enti-
ties as stated above. The number of CD7+ cells was signif-
icantly increased in EAC compared to BE and the
controls (Figure 5a). Colocalization with apoptotic mark-
ers showed a significant difference for CD7+ cells lacking
Bax and caspase 8 expression (Figure 5b). This failure of
apoptotic activity was also observed in natural killer cells
(CD56+), where the number of CD56+ cells expressing
Bcl2 and lack of caspase 8 expression was significantly
decreased in BE compared to EAC (Figure 6).
Discussion
Induction of Barrett's metaplasia and its malignant trans-
formation resulting in esophageal adenocarcinoma has
been a field of great interest since the incidence of these
two disease entities has increased over the last 30 years
[18-20]. The majority of research topics embracing the
molecular biology of BE and EAC focuses on genetic
alterations, which are possibly caused by various genetic,
epigenetic and microenvironmental factors [4,21]. Fur-
thermore, the existing histopathological data on esopha-
geal inflammatory reactions were described in peptic [22]
or eosinophilic esophagitis [23] or analyzed proteins, e.g
cytokines, from the complete mucosa, [24-26]. Despite
the strong functional association between chronic
inflammation and carcinogenesis [10,27] a broad system-
atic analysis of the cell populations causing inflammatory
reaction in the terms of BE and EAC compared to the
healthy esophagus was still missing.
In this study we applied the MELC technology, a unique
and novel technology for high-throughput protein recog-
nition, which enables the investigation of complex pro-
Figure 2 Visualization of the 31 most frequently CMPs in control (A), BE (B) and EAC (C) in a phase contrast image. Each of the 31 different 
colors represents a specific CMP consisting of protein expression signals and lack of protein expression signals. Biopsies were taken from control, BE, 
and EAC mucosa, and MELC staining cycles and data processing were performed as described in the Experimental Procedures section. For the respec-
tive color legend see Additional File 3, Table S2. Figure 2 D-F shows the respective H&E staining for each overlay (magnification 200×) Scalebar 50 μmBerndt et al. Molecular Cancer 2010, 9:177
http://www.molecular-cancer.com/content/9/1/177
Page 5 of 10
Figure 3 Boxplot analysis of the apoptotic activity of different T-cell populations. A, The number of apoptotic T cells is significantly increased in 
BE and EAC compared to the controls. B, C, The number of apoptotic naïve T cells as well as the number of apoptotic memory T cells is significantly 
increased in BE compared to the controls. D, E, The number of apoptotic T-helper cells as well as apoptotic regulatory T cells is significantly increased 
in BE and EAC compared to the controls. F, The number of apoptotic cytotoxic T cells is significantly increased in EAC compared to the controls. Biop-
sies were taken from control, BE, and EAC mucosa and MELC staining cycles and data processing were performed as described in the Experimental 
Procedures section. The respective significance levels are depicted within the graphs.
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tein expression patterns. The main advantages of the
MELC technology over conventional immunohistology
are its capacity to analyze co-localisation of proteins and
missing protein expression, the so-called anti-localization
code. This unique technology allows the creation of a
complete proteome of the tissue. Furthermore, the fact
that a whole tissue section can be analyzed, rather than
just the partial reproduction of cell activity interactions
Figure 4 Boxplot analysis of CMPs containing p53 expression sig-
nals in T cells. The number of T cells with expression of p53 and down-
regulation of Bcl2 und NfkB is significantly increased in BE and EAC 
compared with the controls. Biopsies were taken from control, BE, and 
EAC mucosa and MELC staining cycles and data processing were per-
formed as described in Experimental Procedures. The respective signif-
icance level is depicted within the graph.
CD3
+p53
+Bcl2
-NfkB
-
Figure 5 Boxplot analysis of precursor T cells. A, The number of precursor T cells in BE and EAC is significantly increased in BE and EAC compared 
to the controls. B, The number of precursor T cells without apoptotic activity is increased in BE and EAC compared to the controls. Biopsies were taken 
from control, BE, and EAC mucosa and MELC staining cycles and data processing were performed as described in the Experimental Procedures section. 
The respective significance levels are depicted within the graphs.
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Figure 6 Boxplot analysis of natural killer cells. The number of an-
tiapoptotic natural killer cells is significantly decreased in BE compared 
to EAC. Biopsies were taken from control, BE, and EAC mucosa and 
MELC staining cycles and data processing were performed as de-
scribed in the Experimental Procedures section. The respective signifi-
cance level is depicted within the graph.
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allowed by conventional methods, enables greater objec-
tivity.
Based on the antibody library and the search depth of
five antibodies we identified 4806 different combinatorial
molecular patterns within normal controls, BE and EAC
out of 4.3 × 109 possible patterns. We found the lowest
number of distinct CMP motifs in the group controls vs.
BE. Analyzing these findings in more detail by using nine
different single cell markers for T cells including neutro-
philes we revealed that healthy controls and BE shared T-
helper cells as the most common cell population, explain-
ing the formerly described equal cytokine profiles of non-
inflamed squamous esophagus and BE by Fitzgerald et al.
[25].
In contrast, the highest number of significant different
CMP motifs was found in the group controls vs. EAC.
Indeed, exploring the T-cell distribution in EAC com-
pared to the controls and BE, the position of the T-cell
subpopulations was different.
T cells have the ability to recognize oncogenic precur-
sor signals  and thus prevent malignant tissue transfor-
mation [28]. In normal, resting T cells NfkB is rarely
constitutively expressed. It is upregulated upon activation
[29]. T cells need to be activated and first enter the cell
cycle before undergoing apoptosis [30,31]. Thus, with the
aim of investigating the role of T cells in the transforma-
tion from normal to malignant tissue in the esophagus,
we determined the expression of pro-apoptotic signals
together with NfkB+. In BE and EAC, activated T cells
have a significantly higher caspase expression and, in
turn, a higher apoptosis rate than the controls, suggesting
that in the malignant transformation, immune control
mechanisms are compromised. This finding is further
supported by the increased inability of the immune sys-
tem to control local immune homeostasis, as in EAC reg-
ulatory (CD4+CD25+), and effector (CD8+) T cells appear
to have a higher death rate.
The large amount of CD7 positive cells - which are
ranked before T-helper cells as one of the most important
cell populations of the adaptive immune system - in EAC
was even elevated to a significant level compared to BE.
CD7 is considered to be one of the earliest surface mark-
ers in T-cell ontogeny [32] and can function as a co-stim-
ulatory molecule after T cell activation [33]. In the
context of malignant transformation many lymphomas
wit h a lack of CD7 e x pression ha ve been described t o
date [34,35]. Thus, the first description of an increased
number of progenitor T lymphocytes in EAC should war-
rant further investigations. In contrast to CD7, the role of
natural killer cells (CD56+) as primary responders with an
ability to recognize and lyse tumor cells without previous
sensitization is well known [36]. In our study, despite the
increased number of natural killer cells with expression of
antiapoptotic Bcl2 and down-regulation of caspase 8, nat-
ural killer cells ranked in the last position in EAC. Inter-
pretation of our findings on CD7 and CD56 implies that
the low number of CD56 cells can cause up-regulation of
progenitor T lymphocytes to enforce an immunological
response against the tumor cells.
Given the importance of apoptosis for the homeostatic
control of lymphocyte populations [37,38] as well as the
knowledge that cancer development is linked with an
acquired ability to resist apoptosis [15], we further
focused on the apoptotic activity of the T lymphocytes
within the esophageal mucosa. Apoptotic activity in the
entire T lymphocyte population in BE as well as in EAC
was up-regulated. This result confirms our previously
published findings of increased apoptotic activity of T
cells in colorectal cancer [11]. However, a distinct regula-
tion of apoptotic activity in the various T-cell subpopula-
tions was revealed since the number of apoptotic naïve T
cells and apoptotic memory T cells was increased only in
BE, whereas the number of apoptotic T-helper cells and
apoptotic regulatory T cells was increased in BE and
EAC. Due to the differentiation of naïve T cells into effec-
tor und memory T cells [39] an increased number of
apoptotic naïve T cells may result in a lower number of
effector T cells and, in consequence, in a reduced capac-
ity to act against the development of metaplasia.
Conclusion
In summary, enabled with a novel and unique, multidi-
mensional, fluorescence-based technology, we carried
out the first proteomic analysis of the esophageal mucosa
in the metaplasia-cancer sequence. By investigating key
immune function-related proteins and by in situ detec-
tion of their modification our study demonstrated that
both BE and EAC induce a tremendous modification of
protein expression profiles within the esophageal
mucosa. We showed that, as a consequence, not only the
protein expression at the single cell level is distinct
between controls, BE and EAC, but also the quantity of
the specific immune-competent cell population within
the mucosa changes. The uncovering of distinct and
shared pathways by BE and EAC might thereby help us to
understand pathogenic events that finally result in EAC.
Methods
Patients and sample preparation
A total of 9 biopsies per group (healthy controls, Barrett's
mucosa without dysplasia, and esophageal adenocarci-
noma) were analyzed. All biopsies derived from the
esophageal mucosa and were obtained endoscopically. In
cases of Barrett's mucosa, a pinch biopsy was taken from
the middle to the proximal part of the Barrett's epithe-
lium, and was cut into two segments, one for investiga-
tion by MELC and one for dysplasia grading
confirmation. The biopsies were taken from the middle toBerndt et al. Molecular Cancer 2010, 9:177
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the proximal part of the Barrett's epithelium. The median
age of the patients with BE without dysplasia was 64 years
(range 48-89 years), 8 of them were male and 1 was
female. 6 patients were taking proton pump inhibitors at
the time of tissue sampling. The median age of the
patients suffering from EAC was 62 years (range 51-68
years), 8 of them were male and 1 was female. The biopsy
was taken at the time of first diagnosis, and thus, no
patient had received antitumor therapy. Control patients
underwent upper endoscopy for gastric discomfort, but
all of them had a macroscopically normal appearance.
The median age of the healthy control patients was 59
years (range 36-72 years), 8 of them were male and 1 was
female. All histopathological diagnoses were assessed
from at least two various, board certified pathologists and
at last confirmed by an experienced attending pathologist
(C.R.).
Signed informed consent was obtained from each sub-
ject. Both, the protocol and the consent form were
reviewed and approved by the local ethics committee of
the Charité, Berlin, Germany.
Biopsies were snap frozen in liquid nitrogen, stored at -
80°C, and prepared for MELC analysis as recently
described [14]. Briefly, after embedding the biopsy in Tis-
sue-Tek (Sakura Finetek, Torrance, California, USA) cry-
osections of 5 μm thickness were sliced and applied on
silane coated coverslips. After fixing the tissue with ace-
tone the coverslips were stored at -20°C. In preparation
for the MELC procedure the tissue was fixed once again
with acetone, rehydrated with Dulbecco's PBS, and non-
specific signals were blocked with normal goat serum.
After rinsing the sample five times with PBS analysis of
the tissue with the MELC technique was started.
MELC Technology
MELC Library
The MELC library consists of 31 fluorescence tags
including antibodies, lectins and propidium iodide (PI) as
a nucleic acid dye Additional File 1, Table S1), as recently
published [14]. The antibodies can be divided into the fol-
lowing main groups: phenotype markers (CD3, CD4,
CD8, CD45RA, CD45RO, cytoceratin, collagen IV),
markers for inhibition (Bcl2) and promotion (caspase-3,
caspase-8, PARP-2, p53, Bax) of apoptosis, integrin
expression markers such as CD11a (LFA-1), CD29 (integ-
rin-β1), CD18 (integrin-β2), markers for antigen presen-
tation (CD1a, HLA-DR, HLA-DQ), adhesion molecule
markers (CD2 [LFA-2], CD54 [ICAM-1], CD56 [NKH-1],
CD58 [LFA-3], CD44), markers which suggest an acti-
vated cell status, like CD25 and NfkBp65, and CD57,
CD7, CD71, CD15, WGA for other specific epitopes. Sys-
tematical MELC calibration runs as well as conventional
immunohistochemistry experiments was performed in
order to establish the appropriate working dilutions, fluo-
rophore labels, incubation time (15 min) and positions
within the MELC run [40,41]. As a negative control IgG1
antibody was used at the beginning of each MELC exper-
iment.
Automated microscopic image acquisition by Toponome 
Imaging Cycler® Multi-epitope readout
We used a Toponome Imaging Cycler® MM3 (TIC) pro-
duced by MelTec GmbH & Co. KG, Magdeburg, Ger-
many. This technology platform has been described
previously [40-42]. In brief: The fully automated micro-
scopic robot consists of three parts: (i) an inverted wide-
field fluorescence microscope (Leica DM IRE2; 20× air
lens NA 0.7, filter setups: FITC channel Omega Optical
XF116-2; PE channel - Omega Optical XF111-2) with a
cooled charge-coupled device camera (Apogee KX4,
Apogee Instruments Inc., we use 2 times binning) and
motor-controlled XY-stage, (ii) a pipetting unit, and (iii) a
computer that controls all hardware components of the
robot using MelTecs TIC-Control Software.
After loading the TIC with the specimen, the robot per-
forms the multi-epitope readout as a repetitive cyclic pro-
cess consisting of 4 steps: (1) the incubation of a
fluorochrome-labelled antibody and washing the speci-
men, (2) acquisition of the fluorescence signal and phase
contrast image after correction of any displacement, (3)
soft bleaching of the fluorescent dye until no fluorescence
signal is detectable, and (4) second acquisition of the flu-
orescence signal (postbleaching image) and phase con-
trast image for correction purpose. After completion of
these four steps the next cycle starts with the next anti-
body until the whole experimental design is completed.
Image processing and data mining
Fluorescence images produced by each tag as well as the
postbleaching images were aligned pixel-wise using the
corresponding phase contrast images (accuracy +/- 1
pixel) and were corrected for illumination faults using
flat-field correction. We correct the background by a sub-
traction of the postbleaching image from the following
fluorescence image. A mask-setting process excludes
invalid pixels not belonging to the biological specimen's
information. An experienced histologist together with a
scientist (Ph.D.) experienced in MELC technology
defined the graylevel threshold on 6 selected MELC runs
(two per group) in parallel for each marker separately.
These predefined thresholds were automatically applied
to all corrected fluorescence images of all MELC runs,
reducing the data to binary images comprising the on/off
information for the corresponding epitopes. An example
of the image processing steps is given in Additional File 2,
Figure S1. These images were superimposed to construct
a matrix of combinatorial molecular phenotypes, repre-
senting a binary code of the 32 epitopes' expression in
relation to each pixel (900 × 900 nm2 area) of 1024 × 1024Berndt et al. Molecular Cancer 2010, 9:177
http://www.molecular-cancer.com/content/9/1/177
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pixels. The further analysis dealt with CMP motifs char-
acterizing corresponding pixels. These CMP motifs are
defined as a pixel-related code of 1/0/* ciphering. The
'TopoMiner'/'MotifFinder' software package (MelTec
GmbH & Co. KG, Magdeburg, Germany) was used for
data-mining, as described by Schubert et al. and Berndt
et al. [14,41]. Three pair-wise screens (Wilcoxon rank-
sum test p < 0.0005; search depth n = 5) were performed
to detect differences on the level of pixel frequencies of
the CMP motifs between the three groups (healthy con-
trol, BE, EAC).
Visualization of data of interest
To visualize CMP motifs of interest the 'Topolyzer'
(MelTec GmbH & Co. KG, Magdeburg, Germany) was
used. This software package allows the visualization of
CMP motifs of interest as tables, boxplots [43-45], and
toponome maps on the level of fluorescence and bina-
rized images [46]. Colocalization maps were constructed
by superimposing a set of illumination-adjusted colorized
fluorescence images, each with a distinct color and trans-
parency.
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